Optimal surgical treatment and urological outcomes in boys with pelvic and urogenital rhabdomyosarcomas and soft tissue sarcomas

[1] Stevens MC(2005)Treatment for childhood rhabdomyosarcoma: the cost of cure Lancet Oncol 6 77-84

[2] Raney RB(2001)Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols Sarcoma 5 9-15

[3] Maurer HM(2012)Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and the rationale fro current COG studies Pediatr Blood Cancer 59 5-10

[4] Anderson JR(2012)Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study J Clin Oncol 30 2457-2465

[5] Andrassy RJ(2006)Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group J Clin Oncol 24 3844-3851

[6] Donaldson SS(2005)Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89 J Clin Oncol 23 2618-2628

[7] Qualman SJ(2004)Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery BJU Int 93 125-129

[8] Wharam MD(2004)Results of Treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study-IV, 1991–1997 Pediatr Blood Cancer 42 618-625

[9] Wiener ES(2009)Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children’s oncology group J Clin Oncol 27 3705-3711

[10] Crist WM(2011)Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma trial CWS-96 Pediatr Blood Cancer 56 718-724

[1] Stevens MC(2005)Treatment for childhood rhabdomyosarcoma: the cost of cure Lancet Oncol 6 77-84

[2] Raney RB(2001)Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols Sarcoma 5 9-15

[3] Maurer HM(2012)Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and the rationale fro current COG studies Pediatr Blood Cancer 59 5-10

[4] Anderson JR(2012)Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study J Clin Oncol 30 2457-2465

[5] Andrassy RJ(2006)Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group J Clin Oncol 24 3844-3851

[6] Donaldson SS(2005)Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89 J Clin Oncol 23 2618-2628

[7] Qualman SJ(2004)Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery BJU Int 93 125-129

[8] Wharam MD(2004)Results of Treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study-IV, 1991–1997 Pediatr Blood Cancer 42 618-625

[9] Wiener ES(2009)Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children’s oncology group J Clin Oncol 27 3705-3711

[10] Crist WM(2011)Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma trial CWS-96 Pediatr Blood Cancer 56 718-724